Januvia 50 mg 28 tablets

Januvia 50 mg 28 tablets

Composition:

Each tablet contains:

Sitagliptin 50 mg

Auxiliary components:

Calcium hydrogen phosphate, unmilled, Croscarmellose sodium, Magnesium stearate, Sodium stearyl fumarate

Description:

Januvia (sitagliptin) is an orally active, highly selective inhibitor of the DPP-4 enzyme intended for the treatment of type 2 diabetes mellitus. By inhibiting DPP-4, sitagliptin increases the concentration of two hormones of the incretin family: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide).

Hormones of the incretin family are secreted in the intestine during the day, with their concentration increasing in response to food intake. Incretins are part of the internal physiological system of glucose homeostasis regulation. They enhance insulin secretion and suppress glucagon release in a glucose-dependent manner.

Indications:

-Monotherapy:

As an adjunct to diet and exercise to improve glycemic control in type 2 diabetes.

-Combination therapy:

Type 2 diabetes mellitus to improve glycemic control in combination with metformin or PPAR-γ agonists (e.g., thiazolidinediones) when diet, exercise, and the listed agents alone do not lead to adequate glycemic control.

Method of Administration and Dosage:

-The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor.

-The compliance of the used dosage form of a particular drug with indications for use and the dosage regimen should be strictly observed.

-Taken orally.

-Single dose: 100 mg once daily.

In case of renal failure:

-Correction of the dosage regimen is required.

Contraindications:

-Type 1 diabetes mellitus

-Diabetic ketoacidosis

-Pregnancy

-Lactation period (breastfeeding)

-Children and adolescents under the age of 18

-Hypersensitivity to sitagliptin or any other component of the drug

Precautions:

-Renal insufficiency: Use with caution in patients with renal insufficiency. In case of moderate and severe renal failure, as well as in patients with end-stage renal failure requiring hemodialysis, a dosage adjustment is required.

-Elderly patients: Elderly patients are more likely to develop renal failure. Accordingly, as in other age groups, dose adjustment is necessary in patients with severe renal failure.

Side Effects:

-From the respiratory system:

Upper respiratory tract infections

Nasopharyngitis

-From the nervous system:

Headache

-From the musculoskeletal system:

Arthralgia

-From the digestive system:

Nausea

Vomiting

Abdominal pain

Diarrhea

-Severe reactions:

Acute pancreatitis, including hemorrhagic and necrotic

-Laboratory findings:

An increase in uric acid in the blood

A decrease in the activity of total alkaline phosphatase and, accordingly, the bone fraction of alkaline phosphatase

Leukocytosis due to an increase in the number of neutrophils

Storage Conditions:

Store at a temperature not exceeding 30°C.

Packaging:

A cardboard box holds 28 tablets.